Research graph
References from Author’s response to the editorial commentary, “TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy”. Local targets link to admitted publications; unresolved targets remain external evidence.
Antitumor necrosis factor-like ligand 1A therapy targets tissue inflammation and fibrosis pathways and reduces gut pathobionts in ulcerative colitis
10.1093/ibd/izab193 · 2022 · External reference
Innate lymphoid cells activated by the cytokine TL1A link colitis to emergency granulopoiesis and the recruitment of tumor-promoting neutrophils
10.1016/j.immuni.2025.12.008 · 2026 · External reference
Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study
10.1016/j.cgh.2021.06.011 · 2021 · External reference
P633 first-in-human pharmacokinetic and safety study of an anti-TL1A antibody, TEV-48574, in healthy volunteers and asthma patients
10.1093/ecco-jcc/jjad212.0763 · 2024 · External reference
TL1A drives TH1, TH2 and TH17 pathways in human lamina propria cells in IBD
10.1016/s0016-5085(26)03148-3 · 2026 · External reference
